ES2633767T3 - Anticuerpos contra IL-17BR - Google Patents

Anticuerpos contra IL-17BR Download PDF

Info

Publication number
ES2633767T3
ES2633767T3 ES10712110.5T ES10712110T ES2633767T3 ES 2633767 T3 ES2633767 T3 ES 2633767T3 ES 10712110 T ES10712110 T ES 10712110T ES 2633767 T3 ES2633767 T3 ES 2633767T3
Authority
ES
Spain
Prior art keywords
antibody
antibody molecule
seq
domain
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10712110.5T
Other languages
English (en)
Spanish (es)
Inventor
Andrew Neil James Mckenzie
Daniel Neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2633767T3 publication Critical patent/ES2633767T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES10712110.5T 2009-04-06 2010-03-31 Anticuerpos contra IL-17BR Active ES2633767T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16680809P 2009-04-06 2009-04-06
US166808P 2009-04-06
GBGB0905972.6A GB0905972D0 (en) 2009-04-06 2009-04-06 Antibodies against IL-17BR
GB0905972 2009-04-06
PCT/GB2010/000639 WO2010116123A1 (en) 2009-04-06 2010-03-31 Antibodies against il-17br

Publications (1)

Publication Number Publication Date
ES2633767T3 true ES2633767T3 (es) 2017-09-25

Family

ID=40750206

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10712110.5T Active ES2633767T3 (es) 2009-04-06 2010-03-31 Anticuerpos contra IL-17BR

Country Status (10)

Country Link
US (2) US8586037B2 (enExample)
EP (1) EP2417161B1 (enExample)
JP (1) JP5767625B2 (enExample)
CN (1) CN102482352B (enExample)
AU (1) AU2010233535B2 (enExample)
CA (1) CA2757104C (enExample)
DK (1) DK2417161T3 (enExample)
ES (1) ES2633767T3 (enExample)
GB (1) GB0905972D0 (enExample)
WO (1) WO2010116123A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209485A1 (en) * 2011-10-31 2013-08-15 Riken Therapeutic agent of non-allergic airway inflammation and/or non-allergic hyperresponsive airway
EP2858670B8 (en) * 2012-06-12 2018-09-12 Orega Biotech Antagonists of il-17 isoforms and their uses
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses
US10793628B2 (en) * 2014-06-30 2020-10-06 Academia Sinica Isolated antibodies against interleukin-17 receptor B (IL-17RB) for cancer therapy
US10372718B2 (en) * 2014-11-03 2019-08-06 SavantX, Inc. Systems and methods for enterprise data search and analysis
EP4461311A3 (en) 2015-01-20 2025-03-26 Lankenau Institute for Medical Research Methods and compositions for the treatment of diseases and disorders
JP7623939B2 (ja) * 2018-07-09 2025-01-29 マルチチュード インコーポレーテッド 葉酸受容体アルファに特異的な抗体
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
PL3946377T3 (pl) 2019-04-03 2026-04-20 Orega Biotech Terapie skojarzone oparte na inhibitorach pd1 i il-17b
US20230045494A1 (en) 2020-02-28 2023-02-09 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
WO2025118126A1 (zh) * 2023-12-05 2025-06-12 中国抗体制药有限公司 抗il-17rb抗体、或其抗原结合片段或组合物的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ES2333772T3 (es) * 1999-12-23 2010-03-01 Genentech, Inc. Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
WO2001057202A2 (en) 2000-02-04 2001-08-09 The Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
TWI322154B (en) * 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
US20090068195A1 (en) 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
US8454955B2 (en) 2007-11-28 2013-06-04 Riken Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia
JP2011514335A (ja) 2008-02-21 2011-05-06 アムジェン インコーポレイテッド Ｉｌ−１７ｒａ−ｉｌ−１７ｒｂアンタゴニストおよび該アンタゴニストの使用
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
CN102482352A (zh) 2012-05-30
JP5767625B2 (ja) 2015-08-19
DK2417161T3 (en) 2017-07-31
CA2757104C (en) 2018-07-24
EP2417161A1 (en) 2012-02-15
US20140044718A1 (en) 2014-02-13
EP2417161B1 (en) 2017-05-24
CA2757104A1 (en) 2010-10-14
CN102482352B (zh) 2015-06-10
JP2012522531A (ja) 2012-09-27
AU2010233535B2 (en) 2014-02-27
GB0905972D0 (en) 2009-05-20
AU2010233535A1 (en) 2011-11-03
US20120020985A1 (en) 2012-01-26
US8586037B2 (en) 2013-11-19
US8852589B2 (en) 2014-10-07
HK1170745A1 (en) 2013-03-08
WO2010116123A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
JP5767625B2 (ja) Ｉｌ−１７ｂｒに対する抗体
ES2383809T3 (es) Anticuerpos que se unen al receptor de interleucina 4
JP5366930B2 (ja) Ｉｌ−２５に対する抗体
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
ES2465223T3 (es) Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
ES2424468T3 (es) Miembro de unión para el receptor GM-CSF
ES2463482T3 (es) Anticuerpos que se unen a IL-17a y a IL-17f y procedimientos de uso de los mismos
AU2009299465B2 (en) Antibodies against IL-25
ES3046715T3 (en) Il-5 antibody or antigen binding fragment thereof in medical application
JP2023542394A (ja) ヒトｉｌ－３３に結合する抗体、その調製方法および用途
CN117843776B (zh) 抗体分子、核酸、制药用途及炎性疾病治疗方法
HK1170745B (en) Antibodies against il-17br